Double Your Money with This Biotech [The Motley Fool]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: The Motley Fool
Ardelyx ( NASDAQ:ARDX Shortly thereafter, the same drug successfully achieved the endpoints in a late-stage pivotal trial for a different, albeit larger patient population. The company plans to submit the results to the FDA in mid-00 and hopes to gain approval in 0. Image source: Getty Images. FDA-approved but not launched In September, the FDA approved Ardelyx's drug Ibsrela for the treatment of adults with irritable bowel disease with constipation (IBS-C). Ibsrela, a pill taken twice a day, works via a different mechanism than other approved drugs. Ardelyx's CEO Mike Raab described IBS-C as a "highly burdensome and difficult-to-treat condition affecting more than million people in the United States." Ardelyx, recognizing the challenges of selling a drug for a big market like IBS-C, decided it will seek a commercial partner rather than try to bring the drug to market itself. This will allow the company to keep its focus squarely on advancing Ibsrela as a treatment for another potent
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop [Seeking Alpha]Seeking Alpha
- Ardelyx, Inc. (NASDAQ: ARDX) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $5.50 price target on the stock, down previously from $11.00.MarketBeat
- Ardelyx Responds to District Court Decision Granting Motion to Dismiss [Yahoo! Finance]Yahoo! Finance
- Ardelyx Responds to District Court Decision Granting Motion to DismissGlobeNewswire
- Ardelyx to Participate at the 2024 Jefferies London Healthcare ConferenceGlobeNewswire
ARDX
Earnings
- 10/31/24 - Beat
ARDX
Sec Filings
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- ARDX's page on the SEC website